Results 41 to 50 of about 18,081 (213)

Proprotein convertase genes in Xenopus development [PDF]

Developmental Dynamics, 2005
AbstractProprotein convertases (PCs) are a family of serine endoproteases that proteolytically activate many precursor proteins within various secretory pathway compartments. Loss‐of‐function studies have demonstrated a critical role for these proteases in embryonic patterning and adult homeostasis, yet little is known about how substrate selectivity ...
Sylvia, Nelsen, Linnea, Berg, Crispin, Wong, Jan L, Christian   +3 more
openaire   +2 more sources

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

Journal of Lipid Research, 2007
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease that regulates low density lipoprotein receptor (LDLR) protein levels. The mechanisms of this action, however, remain to be defined.
Yue-Wei Qian, Robert J. Schmidt, Youyan Zhang, Shaoyou Chu, Aimin Lin, He Wang, Xiliang Wang, Thomas P. Beyer, William R. Bensch, Weiming Li, Mariam E. Ehsani, Deshun Lu, Robert J. Konrad, Patrick I. Eacho, David E. Moller, Sotirios K. Karathanasis, Guoqing Cao   +16 more
doaj   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

British Journal of Pharmacology, EarlyView.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang, Sijia Zhu, Na Xing, Zhen Zhou, Jiayi Chen, Tianen Si, Mingrui Li, Lin Jia, Yousef Rastegar‐Kashkooli, Tom J. Wang, Wei Zhu, Jing Li, Chao Jiang, Junmin Wang, Moxin Wu, Xiaoping Yin, Weidong Zang, Jian Wang, Songxue Su   +18 more
wiley   +1 more source

Functional Regulation of Semaphorin Receptors by Proprotein Convertases [PDF]

Journal of Biological Chemistry, 2003
PLEXIN genes encode receptors for secreted and membrane-bound semaphorins. It was proposed that the extracellular domain of plexins acts as an inhibitory moiety, preventing receptor activation. Here we show that plexin-B1 and plexin-B2 undergo proteolytic processing in their extracellular portion, thereby converting single-chain precursors into non ...
ARTIGIANI, Stefania, BARBERIS D, FAZZARI, PIETRO, LONGATI P, ANGELINI P, VAN DE LOO JW, COMOGLIO, Paolo, TAMAGNONE, Luca   +7 more
openaire   +4 more sources

Identification of proprotein convertase substrates using genome-wide expression correlation analysis

BMC Genomics, 2011
Background Subtilisin/kexin-like proprotein convertase (PCSK) enzymes have important regulatory function in a wide variety of biological processes. PCSKs proteolytically process at a target sequence that contains basic amino acids arginine and lysine ...
Turpeinen Hannu, Kukkurainen Sampo, Pulkkinen Kati, Kauppila Timo, Ojala Kalle, Hytönen Vesa P, Pesu Marko   +6 more
doaj   +1 more source

Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease

Frontiers in Pharmacology, 2022
Proprotein convertase subtilisin/kexins (PCSKs) constitute a family of nine related proteases: PCSK1-7, MBTPS1, and PCSK9. Apart from PCSK9, little is known about PCSKs in cardiovascular disease. Here, we aimed to investigate the expression landscape and
Bianca E. Suur, Melody Chemaly, Moritz Lindquist Liljeqvist, Djordje Djordjevic, Djordje Djordjevic, Markus Stenemo, Otto Bergman, Eva Karlöf, Mariette Lengquist, Jacob Odeberg, Jacob Odeberg, Eva Hurt-Camejo, Eva Hurt-Camejo, Per Eriksson, Daniel F.J. Ketelhuth, Daniel F.J. Ketelhuth, Joy Roy, Ulf Hedin, Michael Nyberg, Ljubica Matic   +19 more
doaj   +1 more source

P8 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 LEVELS AND ARTERIAL FUNCTION

Artery Research, 2017
Purpose/Background/Objectives: Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are modestly but significantly associated with increased risk of total cardiovascular events.
Losif Koutagiar, Charalambos Vlachopoulos, Dimitrios Terentes-Printzios, John Skoumas, Nikitas Skliros, Magkas Nikolaos, Antigoni Miliou, Dimitrios Tousoulis   +7 more
doaj   +1 more source

High levels of serum cholesterol increase the risk of developing vessel co‐opting tumors in colorectal cancer liver metastases

The FEBS Journal, EarlyView.
High serum cholesterol is linked to colorectal cancer liver metastases (CRCLM) subtypes with poor survival (replacement pattern). Levels of cholesterol under 4 mmol·L−1 correlated with better survival and a desmoplastic pattern subtype. Furthermore, in vivo PCSK9 inhibitor evolocumab, which lowers cholesterol, reduced liver metastases.
Amatzia Gantz, Audrey Kapelanski‐Lamoureux, Miran Rada, Lucyna Krzywon, Migmar Tsamchoe, Anastasia Tsatoumas, Stephanie K. Petrillo, Nabil G. Seidah, Anthoula Lazaris, Peter Metrakos   +9 more
wiley   +1 more source

Role of PCSK9 inhibitors in the management of dyslipidaemia

Indian Heart Journal
Proprotein convertase subtilisin kexin9 (PCSK9) inhibitors are novel agents that lower LDL cholesterol and reduce cardio-vascular event rate. Being expensive, these agents are reserved for those with high risk or very high risk of CV events and with ...
Tiny Nair
doaj   +1 more source